Considering that patients with insulin resistance show many conjugated metabolic problems such as atherosclerosis, obesity, fatty liver, etc., there have been many efforts to develop sPPARγMs, dual or pan PPAR agonists, with potent efficacy but less-deleterious side effects. Here, PPARA is linked to Obesity.